{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:17:42Z","timestamp":1790036262700,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","heartfailure.onlinejacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jchf.2017.12.016","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:04:02Z","timestamp":1520467442000},"page":"445-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Worsening Heart Failure During the\u00a0Use\u00a0of DPP-4 Inhibitors"],"prefix":"10.1016","volume":"6","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2017.12.016_bib1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.12.016_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diabres.2016.12.004","article-title":"Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia","volume":"123","author":"Nystr\u00f6m","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jchf.2017.12.016_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/dci17-0052","article-title":"Heart failure: the most important, preventable and treatable cardiovascular complication of type 2 diabetes","volume":"41","author":"Packer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2017.12.016_bib4","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1172\/JCI40096","article-title":"Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents","volume":"120","author":"Shimizu","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jchf.2017.12.016_bib5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/187152909789007034","article-title":"Role of PI3K\/AKT, cPLA2 and ERK1\/2 signaling pathways in insulin regulation of vascular smooth muscle cells proliferation","volume":"9","author":"Isenovi\u0107","year":"2009","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.jchf.2017.12.016_bib6","doi-asserted-by":"crossref","first-page":"F957","DOI":"10.1152\/ajprenal.00395.2010","article-title":"Chronic sodium-retaining action of insulin in diabetic dogs","volume":"300","author":"Manhiani","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jchf.2017.12.016_bib7","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","article-title":"Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors","volume":"24","author":"Nichols","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2017.12.016_bib8","doi-asserted-by":"crossref","first-page":"368703","DOI":"10.1155\/2014\/368703","article-title":"The nonglycemic actions of dipeptidyl peptidase-4 inhibitors","volume":"2014","author":"Kim","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jchf.2017.12.016_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)\u2014role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul Pept"},{"key":"10.1016\/j.jchf.2017.12.016_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.pharmthera.2014.03.009","article-title":"Stromal derived factor 1\u03b1: a chemokine that delivers a two-pronged defence of the myocardium","volume":"143","author":"Bromage","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jchf.2017.12.016_bib11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/1574888X11666160614102629","article-title":"Role of stromal-derived factor-1 in mesenchymal stem cell paracrine-mediated tissue repair","volume":"11","author":"Luo","year":"2016","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.jchf.2017.12.016_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pharmthera.2016.07.009","article-title":"Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors","volume":"167","author":"Anderluh","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jchf.2017.12.016_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002081","article-title":"Dipeptidyl peptidase 4 inhibition\u00a0alleviates shortage of circulating glucagon-like peptide-1 in heart failure and\u00a0mitigates myocardial remodeling and\u00a0apoptosis via the exchange protein directly activated by cyclic AMP 1\/Ras-related protein 1 axis","volume":"9","author":"Aoyama","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.12.016_bib14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.111.188086","article-title":"Central actions of the chemokine stromal cell-derived factor 1 contribute to neurohumoral excitation in heart failure rats","volume":"59","author":"Wei","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2017.12.016_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/hh1701.095716","article-title":"Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes","volume":"89","author":"Vila Petroff","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2017.12.016_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cellsig.2015.10.011","article-title":"Comprehensive analysis of chemokine-induced cAMP-inhibitory responses using a real-time luminescent biosensor","volume":"28","author":"Felouzis","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.jchf.2017.12.016_bib17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FJC.0b013e3181f713fe","article-title":"\u03b22-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4","volume":"56","author":"LaRocca","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jchf.2017.12.016_bib18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jcmm.12465","article-title":"Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts","volume":"19","author":"Lee","year":"2015","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jchf.2017.12.016_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1475-2840-13-43","article-title":"Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats","volume":"13","author":"Miyoshi","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2017.12.016_bib20","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0008-6363(00)00142-5","article-title":"Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure","volume":"47","author":"Dam\u00e5s","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2017.12.016_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141408","article-title":"Circulating stromal cell-derived factor 1? levels in heart failure: a matter of proper sampling","volume":"10","author":"Baerts","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2017.12.016_bib22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2353\/ajpath.2010.090574","article-title":"Bone marrow-derived cells contribute to fibrosis in the chronically failing heart","volume":"176","author":"Chu","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jchf.2017.12.016_bib23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCHEARTFAILURE.110.960831","article-title":"CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess","volume":"4","author":"Chu","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.12.016_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133616","article-title":"CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis","volume":"10","author":"Chu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2017.12.016_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/CIRCULATIONAHA.116.025957","article-title":"The diabetic heart failure with preserved ejection fraction phenotype: is it real and is it worth targeting therapeutically?","volume":"135","author":"Lindman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.12.016_bib26","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2016.02.018","article-title":"Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction","volume":"67","author":"Rommel","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.12.016_bib27","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/2047487317717820","article-title":"Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate","volume":"24","author":"Christensen","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jchf.2017.12.016_bib28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cvr\/cvx096","article-title":"Adipose tissue depots and inflammation: effects on plasticity and resident mesenchymal stem cell function","volume":"113","author":"Badimon","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2017.12.016_bib29","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s00125-014-3237-5","article-title":"CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice","volume":"57","author":"Kim","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jchf.2017.12.016_bib30","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2337\/dc17-0061","article-title":"Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1\u03b11-67 in patients with type 2 diabetes","volume":"40","author":"Lovshin","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2017.12.016_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.12.016_bib32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.12.016_bib33","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.12.016_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-017-0593-8","article-title":"A\u00a0randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus","volume":"16","author":"Gantz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2017.12.016_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.12.016_bib36","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.12.016_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1681\/ASN.2016050510","article-title":"Dapagliflozin binds specifically to sodium-glucose cotransporter 2 in the proximal renal tubule","volume":"28","author":"Ghezzi","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jchf.2017.12.016_bib38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jchf.2017.12.016_bib39","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jchf.2017.12.016_bib40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.vph.2011.03.001","article-title":"Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways","volume":"55","author":"Shah","year":"2011","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jchf.2017.12.016_bib41","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCULATIONAHA.105.589937","article-title":"Increase in vascular permeability and vasodilation are critical for proangiogenic effects of stem cell therapy","volume":"114","author":"You","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.12.016_bib42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FJC.0000000000000120","article-title":"Effects of glucagon-like peptide-1 in diabetic rat small resistance arteries","volume":"64","author":"Bayram","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jchf.2017.12.016_bib43","unstructured":"U.S. Food and Drug Administration. Diabetes medications containing saxagliptin and alogliptin: drug safety communication\u2014risk of heart failure. April 5, 2016. Available at: https:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm494252.htm. Accessed January 8,\u00a02018."},{"key":"10.1016\/j.jchf.2017.12.016_bib44","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1161\/CIRCULATIONAHA.115.015511","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"132","author":"Scirica","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.12.016_bib45","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2017.12.016_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial","volume":"1","author":"McGuire","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2017.12.016_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.12.016_bib48","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2337\/db10-0351","article-title":"Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice","volume":"60","author":"Xie","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.jchf.2017.12.016_bib49","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2017.12.016_bib50","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2017.12.016_bib51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pds.1615","article-title":"A\u00a0retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone","volume":"17","author":"Cobitz","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jchf.2017.12.016_bib52","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.12.016_bib53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1159\/000358636","article-title":"PPAR\u03b3-induced stimulation of amiloride-sensitive sodium current in renal collecting duct principal cells is serum and insulin dependent","volume":"33","author":"Chra\u00efbi","year":"2014","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jchf.2017.12.016_bib54","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.9778\/cmajo.20160058","article-title":"Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis","volume":"5","author":"Verma","year":"2017","journal-title":"CMAJ Open"},{"key":"10.1016\/j.jchf.2017.12.016_bib55","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies","volume":"352","author":"Li","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jchf.2017.12.016_bib56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.numecd.2014.01.017","article-title":"Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials","volume":"24","author":"Monami","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jchf.2017.12.016_bib57","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.clinthera.2014.10.009","article-title":"Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?","volume":"36","author":"Clifton","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.jchf.2017.12.016_bib58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.numecd.2016.02.006","article-title":"Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System","volume":"26","author":"Raschi","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jchf.2017.12.016_bib59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4093\/dmj.2015.39.3.247","article-title":"Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance Claims Database","volume":"39","author":"Suh","year":"2015","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jchf.2017.12.016_bib60","doi-asserted-by":"crossref","first-page":"30499","DOI":"10.1038\/srep30499","article-title":"Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: a population-based cohort study","volume":"6","author":"Hung","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jchf.2017.12.016_bib61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2014.09.038","article-title":"Sitagliptin and the risk of hospitalization for heart failure: a population-based study","volume":"177","author":"Wang","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2017.12.016_bib62","first-page":"573","article-title":"Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study","volume":"2","author":"Weir","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2017.12.016_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003957","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study","volume":"10","author":"Kim","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.12.016_bib64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/M15-2568","article-title":"Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study","volume":"164","author":"Toh","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2017.12.016_bib65","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-017-0575-x","article-title":"Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis","volume":"16","author":"Gautam","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2017.12.016_bib66","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2017.12.016_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.12.016_bib68","first-page":"178","article-title":"Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) (letter)","volume":"6","author":"McMurray","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177918300416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177918300416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T21:38:47Z","timestamp":1559338727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177918300416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S2213177918300416"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2017.12.016","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Worsening Heart Failure During the\u00a0Use\u00a0of DPP-4 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2017.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}